ArticleInternational journal of oncology2022

Synergism of a novel MCL‑1 downregulator, acriflavine, with navitoclax (ABT‑263) in triple‑negative breast cancer, lung adenocarcinoma and glioblastoma multiforme.

Anbok Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.